Effects of Linagliptin in Addition to Empagliflozin on Islet Cell Physiology
Status:
Completed
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
The primary aim of this exploratory mechanistic study is to investigate the effects of
Empagliflozin and Linagliptin on alpha- and beta cell physiology in T2DM patients.
This study aims to evaluate the effect of the DPP-IV inhibitor linagliptin (as compared to
placebo) in addition to the SGLT-2 inhibitor empagliflozin on pancreatic alpha and beta cell
function, as well as several markers of metabolic control.